about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Al­ler­gan taps Catal­en­t's Matthew Walsh as CFO; Re­Vi­ral meets end­points in PhI­Ia RSV tri­al

8 years ago
News Briefing

Ken­ji Ya­sukawa takes the reins at Astel­las; Voy­ager hunts for new CEO as Steven Paul goes back to re­search

8 years ago
Peer Review

Voy­ager co-founder Steven Paul steps down from CEO seat; Al­ny­lam en­ters fi­nal stretch at the FDA with patisir­an

8 years ago
News Briefing

UCB, in­vestors back a neu­ro­sciences start­up called Syn­de­si; Ger­many's Biofron­tera in­creas­es US IPO pric­ing range

8 years ago
News Briefing

Sunovion scores on PhI­II Parkin­son's study, shoot­ing for show­down with Acor­da; Puma out-li­cens­es ner­a­tinib to Is­raeli ...

8 years ago
News Briefing

Roche touts CHMP nod for Hem­li­bra; Alder rais­es $200M for mi­graine drug launch

8 years ago
News Briefing

Sor­ry No­vo: Sanofi wins Abl­ynx over with $4.8B buy­out bid, bag­ging nanobody plat­form tech

8 years ago
Deals

Hep­tares co-founder Fiona Mar­shall to lead Mer­ck­'s Lon­don re­search hub; Abl­ynx ap­points Robert Friesen as new CFO

8 years ago
Peer Review

Trail­ing GSK, As­traZeneca of­fers an en­cour­ag­ing look at PhI­II da­ta for three-in-one COPD in­haler

8 years ago
R&D

Fast-grow­ing Shang­hai Phar­ma to plant foot in San Diego, hunt­ing deals in US and Eu­rope

8 years ago
China

In a break­through, Chi­nese re­searchers clone mon­keys hop­ing to pro­vide bet­ter dis­ease mod­els

8 years ago
China

Ex-Al­ler­gan team at Bon­ti rais­es $15.5M for an­oth­er neu­ro­tox­in; Shire com­mits to pub­lish­ing in open ac­cess jour­nals ...

8 years ago
News Briefing

Reck­on­ing the po­ten­tial of CRISPR/Cas9 tech, NIH launch­es $190M genome edit­ing re­search ini­tia­tive

8 years ago
R&D
Discovery

Hep­tares co-founder Fiona Mar­shall grabs the helm at Mer­ck­'s up­com­ing UK drug dis­cov­ery cen­ter

8 years ago
People

In the lat­est set­back to Vi­cal/Astel­las part­ner­ship, lead CMV vac­cine fails a piv­otal PhI­II study

8 years ago
R&D

Big Phar­ma vet John Hohnek­er takes the reins at Anokion; Hep­tares co-founder Fiona Mar­shall re­signs from par­ent ...

8 years ago
Peer Review

Car­mot clos­es $15M round to ad­vance di­a­betes drug; Ar­gos board clears re­verse stock split, moves to small cap mar­ket

8 years ago
News Briefing

France's Owkin rais­es $11M Se­ries A for AI-aid­ed drug de­vel­op­ment; As­traZeneca ex­pands dis­cov­ery deal with X-Chem

8 years ago
News Briefing

Kym­ri­ah gets speedy re­views in US and EU as No­var­tis looks to swift­ly ex­pand CAR-T in­di­ca­tions

8 years ago
R&D
Pharma

Chi­na biotech uni­corn In­novent in talks on $200M IPO and new fund­ing — re­port

8 years ago
Financing

Pre­clin­i­cal study finds Gen­mab may hold the key to a next-gen triple fol­lowup to MEK/BRAF com­bos

8 years ago
Discovery

Why did Abl­ynx board chair­man Pe­ter Fell­ner re­sign in wake of Novo's buy­out of­fer?; Am­gen vet Richard Paul­son tapped ...

8 years ago
Peer Review

Jump­ing on an­ti-ag­ing band­wag­on, Y Com­bi­na­tor joins hunt for the $100B pill

8 years ago
Startups

Charles Riv­er buys KWS BioTest for $20M, gain­ing im­munol­o­gy dis­cov­ery ca­pac­i­ty and a UK foot­print

8 years ago
Deals
Outsourcing
First page Previous page 121122123124125126 Next page Last page
A service from the Financial Times